secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001641172-25-015065
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics stockholders approve capital stock increase and share issuance to YA II PN
--------------------------------------------------------------------------------

- Authorized capital stock increased via amendment to certificate of incorporation effective June 12, 2025.
- Stockholders elected Matthew Link and Victoria Niklas, M.D. as Class II directors until 2028.
- Ratified WithumSmith+Brown, PC as independent auditor for FY 2025; votes: 53,940,908 for, 73,899 against, 528,109 abstain.
- Approved issuance of common stock to YA II PN, LTD., exceeding 7,013,635 shares under Standby Equity Purchase Agreement.
- Proxies representing 54,542,916 votes (77.4% of eligible) were present at the annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000164117225015065/0001641172-25-015065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000164117225015065/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer